336 related articles for article (PubMed ID: 23841079)
21. PET imaging for response assessment in lymphoma: potential and limitations.
Schöder H; Moskowitz C
Radiol Clin North Am; 2008 Mar; 46(2):225-41, viii. PubMed ID: 18619378
[TBL] [Abstract][Full Text] [Related]
22. Positron emission tomography imaging for lymphoma.
Jerusalem G; Hustinx R; Beguin Y; Fillet G
Curr Opin Oncol; 2005 Sep; 17(5):441-5. PubMed ID: 16093792
[TBL] [Abstract][Full Text] [Related]
23. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma.
Macapinlac HA
Mol Imaging Biol; 2004; 6(4):200-7. PubMed ID: 15262235
[TBL] [Abstract][Full Text] [Related]
24. Beyond the lymph nodes: FDG-PET/CT in primary extranodal lymphoma.
Sin KM; Ho SK; Wong BY; Gill H; Khong PL; Lee EY
Clin Imaging; 2017; 42():25-33. PubMed ID: 27875758
[TBL] [Abstract][Full Text] [Related]
25. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma.
Isasi CR; Lu P; Blaufox MD
Cancer; 2005 Sep; 104(5):1066-74. PubMed ID: 16047335
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
27. Impact of FDG-PET/CT in the management of lymphoma.
Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
[TBL] [Abstract][Full Text] [Related]
29. (18)F-Fluorodeoxyglucose PET/MR Imaging in Lymphoma.
Platzek I
PET Clin; 2016 Oct; 11(4):363-73. PubMed ID: 27593243
[TBL] [Abstract][Full Text] [Related]
30. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
31. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation.
Castellucci P; Nanni C; Farsad M; Alinari L; Zinzani P; Stefoni V; Battista G; Valentini D; Pettinato C; Marengo M; Boschi S; Canini R; Baccarani M; Monetti N; Franchi R; Rampin L; Fanti S; Rubello D
Nucl Med Commun; 2005 Aug; 26(8):689-94. PubMed ID: 16000986
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic value of using 18F-FDG PET and PET/CT in immunocompetent patients with primary central nervous system lymphoma: A systematic review and meta-analysis.
Zou Y; Tong J; Leng H; Jiang J; Pan M; Chen Z
Oncotarget; 2017 Jun; 8(25):41518-41528. PubMed ID: 28514747
[TBL] [Abstract][Full Text] [Related]
33. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
34. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?
Kostakoglu L; Goldsmith SJ
Eur J Nucl Med; 2000 Oct; 27(10):1564-78. PubMed ID: 11083548
[TBL] [Abstract][Full Text] [Related]
35. Characterization of radiologically indeterminate lung lesions: 99mTc-depreotide SPECT versus 18F-FDG PET.
Ferran N; Ricart Y; Lopez M; Martinez-Ballarin I; Roca M; Gámez C; Carrerea D; Guirao S; Leon AF; Martin-Comin J
Nucl Med Commun; 2006 Jun; 27(6):507-14. PubMed ID: 16710105
[TBL] [Abstract][Full Text] [Related]
36. Imaging in staging of malignant lymphoma: a systematic review.
Kwee TC; Kwee RM; Nievelstein RA
Blood; 2008 Jan; 111(2):504-16. PubMed ID: 17916746
[TBL] [Abstract][Full Text] [Related]
37. PET and PET/CT in management of the lymphomas.
Podoloff DA; Macapinlac HA
Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533
[TBL] [Abstract][Full Text] [Related]
38. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
39. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
Tirumani SH; LaCasce AS; Jacene HA
PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
[TBL] [Abstract][Full Text] [Related]
40. [F-18 fluorodeoxyglucose positron emission tomography in malignant lymphoma].
Mikosch P
Wien Med Wochenschr; 2002; 152(11-12):269-75. PubMed ID: 12138654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
